Skip to main content
GPN Vaccines on Muck Rack

GPN Vaccines

As seen in: KDVR-TV (Denver, CO), KRON-TV (San Francisco, CA), WJW-TV (Cleveland, OH), WOOD-TV (Grand Rapids, MI), WGN-TV (Chicago, IL), WKRG-TV (Mobile, AL), WKRN-TV (Nashville, TN), KHON-TV (Honolulu, HI), KTVX-TV (Salt Lake City, UT), WAVY-TV (Portsmouth, VA) and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with GPN

Contact GPN, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

GPN Vaccines Reports Positive Safety and Immunogenicity Data from its Phase 1 Trial of Gamma-PN

|
By GPN Vaccines
| WSYR-TV (East Syracuse, NY) Verified
GPN Vaccines Reports Positive Safety and Immunogenicity Data from its Phase 1 Trial of Gamma-PN News provided by GPN Vaccines Jan 03, 2024, 3:30 PM ET , /PRNewswire/ -- GPN Vaccines Ltd, a clinical-stage biotechnology company developing a Streptococcus pneumoniae vaccine to prevent life-threatening pneumonia, bacteraemia and meningitis, is pleased to announce positive safety and immunogenicity data from its Phase 1 trial of Gamma-PN, a non-adjuvanted whole cell-pneumococcal vaccine being...
Open in Who Shared Issue with article?

GPN Vaccines Reports Positive Safety and Immunogenicity Data from its Phase 1 Trial of Gamma-PN

|
By GPN Vaccines
| KGET-TV (Bakersfield, CA) Verified
GPN Vaccines Reports Positive Safety and Immunogenicity Data from its Phase 1 Trial of Gamma-PN News provided by GPN Vaccines Jan 03, 2024, 3:30 PM ET , /PRNewswire/ -- GPN Vaccines Ltd, a clinical-stage biotechnology company developing a Streptococcus pneumoniae vaccine to prevent life-threatening pneumonia, bacteraemia and meningitis, is pleased to announce positive safety and immunogenicity data from its Phase 1 trial of Gamma-PN, a non-adjuvanted whole cell-pneumococcal vaccine being...
Open in Who Shared View Duplicates (203) Issue with article?

GPN Vaccines Reports Positive Safety and Immunogenicity Data from its Phase 1 Trial of Gamma-PN

|
By GPN Vaccines
| WREG-TV (Memphis, TN) Verified
, /PRNewswire/ -- GPN Vaccines Ltd, a clinical-stage biotechnology company developing a Streptococcus pneumoniae vaccine to prevent life-threatening pneumonia, bacteraemia and meningitis, is pleased to announce positive safety and immunogenicity data from its Phase 1 trial of Gamma-PN, a non-adjuvanted whole cell-pneumococcal vaccine being investigated in adults aged 50 to 69 years.
Open in Who Shared View Duplicates (2) Issue with article?
See all 93 articles